SEPN Stock Analysis: Septerna, Common Stock | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.750m USD | 12M Return: 149.5% | US81734D1046 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 16.1M
Qual. Beats: 0
Rev. Trend: 98.4%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 1.8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Septerna, Inc. is a clinical-stage biotechnology company that discovers and develops oral small molecule therapies targeting G protein-coupled receptors (GPCRs) - the largest family of cell surface receptors and a major class of drug targets - for endocrinology, immunology/inflammation, and metabolic diseases. Its lead programs include an oral PTH1R agonist for hypoparathyroidism, SEP-631 (an MRGPRX2 negative allosteric modulator) for chronic spontaneous urticaria and mast cell diseases, and an oral TSHR NAM for Graves disease and thyroid eye disease, with additional exploratory work in neurology, womens health, cardiovascular, and respiratory indications. The company maintains a global collaboration and license agreement with Novo Nordisk to develop oral small molecule therapies for metabolic-related diseases. Founded in 2019 and headquartered in South San Francisco, California, Septerna was formerly known as GPCR NewCo, Inc. before adopting its current name in June 2021. As a clinical-stage company with no approved products, its business model centers on advancing candidates through early-stage trials and monetizing its pipeline through partnerships.
- PTH1R oral agonist Phase 1 data expected mid-2025
- Novo Nordisk collaboration delivers milestone payments and R&D funding
- Cash runway supports pipeline through key 2025-2026 clinical readouts
| Net Income: -24.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.19 > 0.02 and ΔFCF/TA 38.54 > 1.0 |
| NWC/Revenue: 320.4% < 20% (prev 43.9k%; Δ -43.6k% < -1%) |
| CFO/TA 0.19 > 3% & CFO 106.0m > Net Income -24.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.99 > 1.5 & < 3 |
| Outstanding Shares: last quarter (45.0m) vs 12m ago 1.98% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 20.14% > 50% (prev 0.17%; Δ 19.96% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.56 (Total Current Assets 396.2m - Total Current Liabilities 79.3m) / Total Assets 566.7m |
| B: -0.33 (Retained Earnings -188.9m / Total Assets 566.7m) |
| C: -0.09 (EBIT TTM -43.5m / Avg Total Assets 491.0m) |
| D: 2.15 (Book Value of Equity 386.7m / Total Liabilities 180.0m) |
| Altman-Z'' = 4.24 = AA |
| DSRI: 0.10 (Receivables 15.9m/2.57m, Revenue 98.9m/726k) |
| GMI: 1.02 (GM 100.0% / 98.38%) |
| AQI: 1.99 (AQ_t 0.26 / AQ_t-1 0.13) |
| SGI: 136.2 (Revenue 98.9m / 726k) |
| TATA: -0.23 (NI -24.2m - CFO 106.0m) / TA 566.7m) |
| Beneish M = 93.75 (Cap -4..+1) = D |
As of September 10, 2026, the stock is trading at USD 37.97 with a total of 475,286 shares traded. Over the past week, the price has changed by +0.77%, over one month by -2.27%, over three months by +22.44% and over the past year by +149.47%.
Current recommended Stop Loss: 35.60 (which is 6.2% or 1.2 ATR below the current price).
Septerna, Common Stock has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy SEPN.
- StrongBuy: 2
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 54.2 | 42.8% |
P/E Forward = 107.5269
P/S = 17.7867
P/B = 4.8811
Revenue TTM = 98.9m USD
EBIT TTM = -43.5m USD
EBITDA TTM = -41.9m USD
Long Term Debt = 20.1m USD (estimated: total debt 22.5m - short term 2.41m)
Short Term Debt = 2.41m USD (from shortTermDebt, last quarter)
Debt = 22.5m USD (from shortLongTermDebtTotal, last quarter) (leases 23.1m already included)
Net Debt = -349.8m USD (calculated: Debt 22.5m - CCE 372.3m)
Enterprise Value = 1.40b USD (1.75b + Debt 22.5m - CCE 372.3m)
Interest Coverage Ratio = unknown (Ebit TTM -43.5m / Interest Expense TTM 0.0)
EV/FCF = 13.33x (Enterprise Value 1.40b / FCF TTM 105.1m)
FCF Yield = 7.50% (FCF TTM 105.1m / Enterprise Value 1.40b)
FCF Margin = 106.3% (FCF TTM 105.1m / Revenue TTM 98.9m)
Net Margin = -24.51% (Net Income TTM -24.2m / Revenue TTM 98.9m)
Gross Margin = unknown ((Revenue TTM 98.9m - Cost of Revenue TTM 1.60m) / Revenue TTM)
Tobins Q-Ratio = 2.47 (Enterprise Value 1.40b / Total Assets 566.7m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 22.5m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -34.4m (EBIT -43.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.99 (Total Current Assets 396.2m / Total Current Liabilities 79.3m)
Debt / Equity = 0.06 (Debt 22.5m / totalStockholderEquity, last quarter 386.7m)
Debt / EBITDA = 8.34 (negative EBITDA) (Net Debt -349.8m / EBITDA -41.9m)
Debt / FCF = -3.33 (Net Debt -349.8m / FCF TTM 105.1m)
Total Stockholder Equity = 384.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -4.94% (Net Income -24.2m / Total Assets 566.7m)
RoE = -6.31% (Net Income TTM -24.2m / Total Stockholder Equity 384.0m)
RoCE = -10.78% (EBIT -43.5m / Capital Employed (Equity 384.0m + L.T.Debt 20.1m))
RoIC = -7.09% (negative operating profit) (NOPAT -34.4m / Invested Capital 484.9m)
WACC = 12.15% (E(1.75b)/V(1.77b) * Re(12.31%) + D(22.5m)/V(1.77b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 12.31% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 46.84 | Cagr: 3.15%
[DCF] Terminal Value 63.33% ; FCFF base≈105.1m ; Y1≈105.5m ; Y5≈111.8m
[DCF] Fair Price = 30.12 (EV 1.06b - Net Debt -349.8m = Equity 1.41b / Shares 46.7m; r=12.15% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.04 | # QB: 0
Revenue Correlation: 98.40 | Revenue CAGR: 1.64k% | SUE: 0.24 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.63 | Chg30d=-13.23% | Revisions=+0% | Analysts=4
EPS current Year (2026-12-31): EPS=-1.19 | Chg30d=+35.46% | Revisions=+25% | GrowthEPS=+14.4% | GrowthRev=+109.0%
EPS next Year (2027-12-31): EPS=-1.94 | Chg30d=+27.01% | Revisions=+17% | GrowthEPS=-63.5% | GrowthRev=-23.3%
[Analyst] Revisions Ratio: +22% (up=4, down=2)